BriaCell Therapeutics Corp (BCTX)

Over the past six months, BriaCell received positive recommendations from the DSMB for its Phase 3 Bria-ABC study and reported sustained resolution of lung metastasis in a Bria-OTS patient. The company presented positive Phase 2 survival and Phase 3 clinical data at SABCS®. BriaCell's Phase 3 Bria-IMT trial was featured in Nature Medicine. The company announced poster presentations at the 2026 AACR Annual Meeting and an asset purchase transaction for a soluble CD80 license. The share price experienced a significant decline of 90.14% between March 25, 2025, and March 24, 2026, with a 52-week range between $3.60 and $98.20.

BriaCell Therapeutics Corp.'s products and services are not subject to traditional demand seasonality. Demand is driven by ongoing clinical trials, regulatory milestones, and the prevalence of the diseases it aims to treat.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, particularly metastatic breast cancer and other solid tumors. Its lead product candidate is Bria-IMT™, currently in a pivotal Phase 3 clinical study. Other platforms include Bria-OTS™, Bria-OTS+™ (with candidates like Bria-BRES+™ and Bria-PROS+™), and a soluble CD80 protein therapeutic. BriaCell also has a subsidiary, BriaPro Therapeutics Corp., focused on small-molecule and binding-agent discovery.

BriaCell Therapeutics Corp. is headquartered in West Vancouver, British Columbia, Canada. Its common shares are traded on The Nasdaq Stock Market LLC (BCTX), the Toronto Stock Exchange (BCT), and Deutsche Boerse AG and Munich Stock Exchange (8BT).

BriaCell Therapeutics Corp. has maintained a positive brand reputation over the past year due to favorable clinical trial outcomes and recognition within the scientific and medical communities. The company has reported positive data from its Phase 2 and Phase 3 studies for Bria-IMT, and the Bria-IMT regimen continues under FDA Fast Track Designation. BriaCell has presented its data at major oncology and immunotherapy meetings, and its Phase 3 Bria-IMT trial was featured in Nature Medicine.

BriaCell Therapeutics Corp. has a diverse ownership structure. As of December 2025, 12 institutions held 9.66K shares, with institutional investors owning approximately 15.42% of the stock. Individual insiders own about 2.52% of the shares, with Marc Lustig being the largest individual shareholder, owning 57.69% of the company's shares. Hedge funds own 9.07%, and the general public owns 86%.